BeOne Medicines (ONC) Total Debt (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Total Debt data on file, last reported at $959.1 million in Q1 2026.

• On a quarterly basis, Total Debt rose 3.84% year-over-year to $959.1 million in Q1 2026; TTM through Mar 2026 was $959.1 million, a 3.84% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, changed 0.12% from the prior year.
• Total Debt for Q1 2026 stood at $959.1 million, down from $1.0 billion in the prior quarter.
• Over the last five years, Total Debt for ONC reached as high as $1.1 billion in Q3 2024 and fell as low as $191.8 million in Q3 2025.
• Historically, Total Debt has averaged $752.8 million across 5 years, with a median of $886.0 million in 2023.
• Across the five-year window, Total Debt soared 241.88% in 2023 and plunged 81.75% in 2025, its largest moves.
• Year by year, Total Debt stood at $259.1 million in 2022, then surged by 241.88% to $886.0 million in 2023, then grew by 14.9% to $1.0 billion in 2024, then increased by 0.12% to $1.0 billion in 2025, then dropped by 5.9% to $959.1 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $959.1 million in Q1 2026, $1.0 billion in Q4 2025, and $191.8 million in Q3 2025.